Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 26(21): 5247-5253, 2016 11 01.
Article in English | MEDLINE | ID: mdl-27720295

ABSTRACT

Trypanosoma brucei are protozoan parasites that cause African sleeping sickness in humans (also known as Human African Trypanosomiasis-HAT). Without treatment, T. brucei infections are fatal. There is an urgent need for new therapeutic strategies as current drugs are toxic, have complex treatment regimens, and are becoming less effective owing to rising antibiotic resistance in parasites. We hypothesize that targeting the HSP60/10 chaperonin systems in T. brucei is a viable anti-trypanosomal strategy as parasites rely on these stress response elements for their development and survival. We recently discovered several hundred inhibitors of the prototypical HSP60/10 chaperonin system from Escherichia coli, termed GroEL/ES. One of the most potent GroEL/ES inhibitors we discovered was compound 1. While examining the PubChem database, we found that a related analog, 2e-p, exhibited cytotoxicity to Leishmania major promastigotes, which are trypanosomatids highly related to Trypanosoma brucei. Through initial counter-screening, we found that compounds 1 and 2e-p were also cytotoxic to Trypanosoma brucei parasites (EC50=7.9 and 3.1µM, respectively). These encouraging initial results prompted us to develop a library of inhibitor analogs and examine their anti-parasitic potential in vitro. Of the 49 new chaperonin inhibitors developed, 39% exhibit greater cytotoxicity to T. brucei parasites than parent compound 1. While many analogs exhibit moderate cytotoxicity to human liver and kidney cells, we identified molecular substructures to pursue for further medicinal chemistry optimization to increase the therapeutic windows of this novel class of chaperonin-targeting anti-parasitic candidates. An intriguing finding from this study is that suramin, the first-line drug for treating early stage T. brucei infections, is also a potent inhibitor of GroEL/ES and HSP60/10 chaperonin systems.


Subject(s)
Antiprotozoal Agents/pharmacology , Chaperonin 10/drug effects , Chaperonin 60/drug effects , Trypanosoma brucei brucei/metabolism , Trypanosomiasis, African/drug therapy , Animals , Antiprotozoal Agents/therapeutic use , Drug Evaluation, Preclinical , High-Throughput Screening Assays , Humans
2.
Protein Eng ; 14(6): 391-5, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11477217

ABSTRACT

Chaperonin-10s possess a highly flexible segment of approximately 10 residues that covers their dome-like structure and closes the central cavity of the chaperonin assembly. The dome loop is believed to contribute to the plasticity of their oligomeric structure. We have exploited the presence of a single tryptophan residue occurring in the dome loop of Mycobacterium tuberculosis chaperonin-10 (cpn-10), and through intrinsic fluorescence measurements show that in the absence of metal ions, the tryptophan is almost fully solvent exposed at neutral pH. The dome loop, however, assumes a closed conformation in the presence of metal ions, or at low pH. These changes are fully reversed in the presence of chelating agents such as EDTA, confirming the role of cations in modulating the metastable states of cpn-10.


Subject(s)
Chaperonin 10/chemistry , Metals/pharmacology , Amino Acid Sequence , Cations/pharmacology , Chaperonin 10/drug effects , Chelating Agents/pharmacology , Dimerization , Hydrogen-Ion Concentration , Molecular Sequence Data , Mycobacterium tuberculosis/chemistry , Pliability/drug effects , Protein Conformation/drug effects , Protein Structure, Tertiary/drug effects , Sequence Alignment , Solvents/metabolism , Spectrometry, Fluorescence , Tryptophan/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...